Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Y-632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo.

Wang W, Liu Y, Zhao Z, Xie C, Xu Y, Hu Y, Quan H, Lou L.

Cancer Sci. 2016 Jun;107(6):782-90. doi: 10.1111/cas.12934. Epub 2016 Apr 27.

2.

The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia.

Ko TK, Chin HS, Chuah CT, Huang JW, Ng KP, Khaw SL, Huang DC, Ong ST.

Oncotarget. 2016 Jan 19;7(3):2721-33. doi: 10.18632/oncotarget.5436.

3.

Low expression of Abelson interactor-1 is linked to acquired drug resistance in Bcr-Abl-induced leukemia.

Chorzalska A, Salloum I, Shafqat H, Khan S, Marjon P, Treaba D, Schorl C, Morgan J, Bryke CR, Falanga V, Zhao TC, Reagan J, Winer E, Olszewski AJ, Al-Homsi AS, Kouttab N, Dubielecka PM.

Leukemia. 2014 Nov;28(11):2165-77. doi: 10.1038/leu.2014.120. Epub 2014 Apr 4.

4.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

5.

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R.

Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004.

6.

Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.

Zhu Jf, Li Zj, Zhang Gs, Meng K, Kuang Wy, Li J, Zhou Xf, Li Rj, Peng Hl, Dai Cw, Shen JK, Gong Fj, Xu Yx, Liu Sf.

PLoS One. 2011;6(8):e23720. doi: 10.1371/journal.pone.0023720. Epub 2011 Aug 22.

7.

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

Joha S, Nugues AL, Hétuin D, Berthon C, Dezitter X, Dauphin V, Mahon FX, Roche-Lestienne C, Preudhomme C, Quesnel B, Idziorek T.

Oncogene. 2012 Mar 15;31(11):1419-30. doi: 10.1038/onc.2011.328. Epub 2011 Aug 1.

8.

The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells.

Pellicano F, Simara P, Sinclair A, Helgason GV, Copland M, Grant S, Holyoake TL.

Leukemia. 2011 Jul;25(7):1159-67. doi: 10.1038/leu.2011.67. Epub 2011 Apr 12.

9.

Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

Bright SA, McElligott AM, O'Connell JW, O'Connor L, Carroll P, Campiani G, Deininger MW, Conneally E, Lawler M, Williams DC, Zisterer DM.

Br J Cancer. 2010 May 11;102(10):1474-82. doi: 10.1038/sj.bjc.6605670. Epub 2010 Apr 20.

10.

The bone marrow microenvironment as a sanctuary for minimal residual disease in CML.

Nair RR, Tolentino J, Hazlehurst LA.

Biochem Pharmacol. 2010 Sep 1;80(5):602-12. doi: 10.1016/j.bcp.2010.04.003. Epub 2010 Apr 9. Review.

11.

Pro-oncogenic and anti-oncogenic pathways: opportunities and challenges of cancer therapy.

Zhang J, Chen YH, Lu Q.

Future Oncol. 2010 Apr;6(4):587-603. doi: 10.2217/fon.10.15. Review.

12.

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.

Aceves-Luquero CI, Agarwal A, Callejas-Valera JL, Arias-González L, Esparís-Ogando A, del Peso Ovalle L, Bellón-Echeverria I, de la Cruz-Morcillo MA, Galán Moya EM, Moreno Gimeno I, Gómez JC, Deininger MW, Pandiella A, Sánchez Prieto R.

PLoS One. 2009 Jul 1;4(7):e6124. doi: 10.1371/journal.pone.0006124.

13.

STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner.

Sims JT, Ganguly S, Fiore LS, Holler CJ, Park ES, Plattner R.

Biochem Pharmacol. 2009 Aug 1;78(3):249-60. doi: 10.1016/j.bcp.2009.04.007. Epub 2009 Apr 14.

14.

Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.

Zhang M, Fu W, Prabhu S, Moore JC, Ko J, Kim JW, Druker BJ, Trapp V, Fruehauf J, Gram H, Fan HY, Ong ST.

Mol Cell Biol. 2008 Oct;28(20):6496-509. doi: 10.1128/MCB.00477-08. Epub 2008 Aug 11.

15.

Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?

Kälsch AI, Soboletzki M, Schmitt WH, van der Woude FJ, Hochhaus A, Yard BA, Birck R.

Clin Exp Immunol. 2008 Mar;151(3):391-8. doi: 10.1111/j.1365-2249.2007.03572.x. Epub 2008 Jan 10.

16.

Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis.

Johnson DE.

Adv Enzyme Regul. 2008;48:98-112. Epub 2007 Nov 19. Review. No abstract available.

17.

FoxO tumor suppressors and BCR-ABL-induced leukemia: a matter of evasion of apoptosis.

Jagani Z, Singh A, Khosravi-Far R.

Biochim Biophys Acta. 2008 Jan;1785(1):63-84. Epub 2007 Oct 16. Review.

18.

Aberrant cytokine signaling in leukemia.

Van Etten RA.

Oncogene. 2007 Oct 15;26(47):6738-49. Review.

19.

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.

Tortora G, Bianco R, Daniele G, Ciardiello F, McCubrey JA, Ricciardi MR, Ciuffreda L, Cognetti F, Tafuri A, Milella M.

Drug Resist Updat. 2007 Jun;10(3):81-100. Epub 2007 May 7. Review.

20.

High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2 dependent suppression of C/EBPalpha-driven myeloid differentiation.

Chang JS, Santhanam R, Trotta R, Neviani P, Eiring AM, Briercheck E, Ronchetti M, Roy DC, Calabretta B, Caligiuri MA, Perrotti D.

Blood. 2007 Aug 1;110(3):994-1003. Epub 2007 May 2.

Supplemental Content

Support Center